Key result
Cardiac troponins offer the highest sensitivity and specificity as the diagnostic gold standard for AMI.
Answers are grounded in this paper and cite their sources.
This review summarizes the historical evolution of cardiac biomarkers, highlighting the role of high-sensitivity cardiac troponins as the definitive test for diagnosing myocardial infarction.
Acute coronary syndrome (ACS) is one of the leading causes of admission to the emergency departments (EDs) worldwide. The diagnosis of ACS involves the evaluation of clinical signs and symptoms, electrocardiographic assessment, and measurement of cardiac circulating biomarkers. In the last 60 years, the use of laboratory markers has changed considerably. Early biomarker assessment has entailed testing for total enzyme activity of aspartate aminotransferase (AST), lactate dehydrogenase (LDH), and creatine kinase (CK) but was highly nonspecific. Soon thereafter, the development of immunoassays, as well as technical advances in automation, allowed the measurements of the CK MB isoenzyme (CK-MB) in mass rather than in activity and myoglobin. Currently, cardiac troponins (CTn) have the highest sensitivity and specificity for myocardial necrosis and represent the biochemical gold standard for diagnosing acute myocardial infarction (AMI). This review provides a chronology of the major events that marked the evolution of cardiac biomarker testing and the development of the relative assays from the first introduction of AST in the 1950s to the last high-sensitivity troponin immunoassays in the 2010s.
No takes yet. Share an insight, caveat, or question.
Mohan et al. (2017) conducted a review in Acute Coronary Syndrome. Cardiac biomarkers was evaluated. Cardiac troponins currently have the highest sensitivity and specificity for myocardial necrosis, representing the biochemical gold standard for diagnosing acute myocardial infarction.
Synapse has enriched 10 related papers. Consider them for comparative context: